Hormonal
GLP-1 receptor agonists (GLP-1RAs) provide high glycemic efficacy and facilitate weight loss in type 2 diabetes without conferring a risk of hypoglycemia.
GLP-1 receptor agonists are injectable medications that effectively lower blood sugar and help with weight loss in type 2 diabetes without causing low blood sugar. They come in daily or weekly formulations. Side effects like nausea are common initially but often improve over time. They are particularly useful for patients who need to avoid weight gain or hypoglycemia associated with other diabetes medications like insulin or sulfonylureas.
GLP-1 RAs have demonstrated a high level of glycemic efficacy, without conferring risk of hypoglycemia, while physiologically facilitating weight loss.
Why this rating
Based on a review of multiple phase 3 randomized controlled trials (RCTs).
Source
A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
Vanita R. Aroda · Diabetes Obesity and Metabolism · 2018
DOI 10.1111/dom.13162
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →